Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent:30-day stroke rate and complications
Standard
Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent:30-day stroke rate and complications. / von Schoenfeldt, Patrick; Krützelmann, Anna; Bußmeyer, Matthias; Mpotsaris, Anastasios; Rosenkranz, Michael; Fiehler, Jens; Weber, Werner; Buhk, Jan-Hendrik.
In: J NEUROINTERV SURG, Vol. 7, No. 3, 2014, p. 188-193.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent:30-day stroke rate and complications
AU - von Schoenfeldt, Patrick
AU - Krützelmann, Anna
AU - Bußmeyer, Matthias
AU - Mpotsaris, Anastasios
AU - Rosenkranz, Michael
AU - Fiehler, Jens
AU - Weber, Werner
AU - Buhk, Jan-Hendrik
PY - 2014
Y1 - 2014
N2 - BACKGROUND AND PURPOSE: Analysis of procedural results and 30-day outcome after intracranial angioplasty and stenting (ICAS) with the balloon-expandable Pharos Vitesse stent system in carefully selected high-risk patients in two high-volume neurovascular centers.MATERIALS AND METHODS: 92 patients scheduled for elective ICAS using Pharos Vitesse between August, 2008 and August, 2011 were included. All patients showed high-grade intracranial stenosis and recurrent ischemic events despite best medical treatment at that time. The stroke rates and complications were divided into procedural and 30-day short-term events.RESULTS: Successful stent placement was achieved in all but one patient. Ischemic procedural complications occurred in three subjects. 30-Day complications and strokes were seen in four patients: two minor ischemic strokes, one fatal hemorrhage and one non-stroke-related death. Overall, strokes occurred in 6 out of 92 patients (6.5%, 95% CI 3.0% to 13.5%). The total stroke and death rate was 7.6% (95% CI 3.7% to 14.9%). No significant correlation with previously reported risk factors could be found, although a higher rate of ischemic strokes (four out of five) in the posterior circulation was recorded.CONCLUSIONS: In patients with intracranial stenosis who experience recurrent ischemic events despite best medical treatment, ICAS, using the balloon-expandable Pharos Vitesse stent, may still be considered as an individual treatment option in high-volume neurovascular centers.
AB - BACKGROUND AND PURPOSE: Analysis of procedural results and 30-day outcome after intracranial angioplasty and stenting (ICAS) with the balloon-expandable Pharos Vitesse stent system in carefully selected high-risk patients in two high-volume neurovascular centers.MATERIALS AND METHODS: 92 patients scheduled for elective ICAS using Pharos Vitesse between August, 2008 and August, 2011 were included. All patients showed high-grade intracranial stenosis and recurrent ischemic events despite best medical treatment at that time. The stroke rates and complications were divided into procedural and 30-day short-term events.RESULTS: Successful stent placement was achieved in all but one patient. Ischemic procedural complications occurred in three subjects. 30-Day complications and strokes were seen in four patients: two minor ischemic strokes, one fatal hemorrhage and one non-stroke-related death. Overall, strokes occurred in 6 out of 92 patients (6.5%, 95% CI 3.0% to 13.5%). The total stroke and death rate was 7.6% (95% CI 3.7% to 14.9%). No significant correlation with previously reported risk factors could be found, although a higher rate of ischemic strokes (four out of five) in the posterior circulation was recorded.CONCLUSIONS: In patients with intracranial stenosis who experience recurrent ischemic events despite best medical treatment, ICAS, using the balloon-expandable Pharos Vitesse stent, may still be considered as an individual treatment option in high-volume neurovascular centers.
U2 - 10.1136/neurintsurg-2013-011019
DO - 10.1136/neurintsurg-2013-011019
M3 - SCORING: Journal article
C2 - 24510379
VL - 7
SP - 188
EP - 193
JO - J NEUROINTERV SURG
JF - J NEUROINTERV SURG
SN - 1759-8478
IS - 3
ER -